Economic support to patients in HIV and TB grants in Rounds 7 and 10 from the Global Fund to Fight AIDS, Tuberculosis and Malaria

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Richter, Linda M ^a,b   Lönnroth, Knut ^c   Desmond, Chris ^a,b   Jackson, Robin ^d   Jaramillo, Ernesto ^c   Weil, Diana ^c  

^a HUMAN SCIENCES RESEARCH COUNCIL   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d World Food Programme   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BUDGET; FUNDING; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; SOCIAL ASPECT; TUBERCULOSIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ECONOMICS; HEALTH; HEALTH CARE DELIVERY; INTERNATIONAL COOPERATION; MALARIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DELIVERY OF HEALTH CARE; GLOBAL HEALTH; HUMANS; INTERNATIONAL COOPERATION; MALARIA; TUBERCULOSIS;

EID: 84900333032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086225     Document Type: Article

References (50)

1. Burström B (2009) Market-oriented, demand-driven health care reforms and equity in health and health care utilization in Sweden. Int J Health Serv 39:, 271-285.
2. Peters D, Garg A, Bloom G, Walker D, Brieger W, et al. (2007) Poverty and access to health care in developing countries. Ann NY Acad 1136: 161-171.
3. Qian D, Pong R, Yin A, Nagarajan K, Meng Q (2009) Determinants of health care demand in poor, rural China: The case of Gansu Province. Health Polic Plann 24: 2324-334.
4. Marmot M (2005) Social determinants of health inequalities. Lancet 365: 1099-1104.
5. Van Doorslaer E, O'Donnell O, Rannan-Eliya R, Somanathan A, Adhikari S, et al. (2006) Effect of payments for health care on poverty estimates in 11 countries in Asia: An analysis of household survey data. Lancet 368: 1357-1364. (Pubitemid 44559666)
6. Ukwaja K, Modebe O, Igwenyi C, Alobu I (2012) The economic burden of tuberculosis care for patients and households in Africa: A systematic review. Int J Tuberc Lung Dis 16: 733-739.
7. Kamolratanakul P, Sawert H, Kongsin S, Lertmaharit S, Sriwongsa J, et al. (2000) Economic impact of tuberculosis at the household level. Int J Tuberc Lund Dis 3: 596-602.
8. Muniyandi M, Ramachandran R, Balasubramanian R (2005) Costs to patients with tuberculosis treated under DOTS programme. Indian J of Tub 52: 188-196. (Pubitemid 43018956)
9. Mauch V, Bonsu F, Gyapong M, Suarez P, Marcelino B, et al. (2012) Free TB diagnosis and treatment are not enough - Patient cost evidence from three continents. Int J Tuberc Lung Dis 7: 381-387.
10. Jackson S, Sleigh AC, Wang G-J, Liu X-L (2006) Poverty and the economic effects of TB in rural China. Int J Tuberc Lung Dis 10: 1104-1110. (Pubitemid 44519347)
11. Lönnroth K, Aung T, Maung W, Kluge H, Uplekar M (2007) Social franchising of TB care through private GPs in Myanmar: An assessment of treatment results, access, equity and financial protection. Health Polic Plann 22: 156-166. (Pubitemid 47355780)
12. Pantoja A, Floyd K, Unnikrishnan K, Jitendra R, Padma M, et al. (2009) Economic valuation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis 13: 698-704.
13. Rouzier VA, Oxlade O, Verduga R, Gresely L, Mezies D (2010) Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis in Ecuador. Int J Tuberc Lung Dis 14: 1316-1322.
14. Pichenda K, Nakamura K, Morita A, Kizuki M, Seino K, et al. (2012) Nonhospital DOT and early diagnosis of tuberculosis reduce costs while achieving treatment success. Int J Tuberc Lung Dis 16: 828-834.
15. Storla D, Yimer S, Bjune G (2008) A systematic review of delay in the diagnosis and treatment of tuberculosis. 8, 15. doi:10.1186/1471-2458-8-15.
16. Munro S, Lewin S, Smith H, Engel M, Fretheim A, Volmink J (2007) Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med 4: doi:10.1371/journal.pmed.0040238.
17. Waitt C, Squire S (2011) A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis 15: 871-885.
18. Lutge E, Wiysonge C, Knight S, Volmink J (2012) Material incentive and enablers in the management of tuberculosis. Cochrane Database Systematic Review, 1, CD007952.
19. Lutge E, Lewin S, Volmink J, Friedman I, Lombard C (2013). Economic support to improve tuberculosis treatment outcomes in South Africa: A pragmatic cluster randomized control trial. Trials 14: 154.
20. Toczek A, Cox H, du Cros P, Cooke G, Ford N (2013) Strategies for reducing treatment default in drug-resistant tuberculosis: Systematic review and metaanalysis. Int J Tuberc Lung Dis 17: 299-307.
21. Volmink J,Garner P (2000) Interventions for promoting adherence to tuberculosis management. Cochrane Database of Systematic Reviews, 2, CD000010.
22. Hirsch-Moverman Y, Daftary A, Franks J, Colson P (2008) Adherence to treatment for latent tuberculosis infection: Systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 12: 1235-1254.
23. Beith A, Eichler R, Weil D (2009) Worldwide: Incentives for tuberculosis diagnosis and treatment. In Eichler R, Levine R and the Performance-Based Incentives working Group, editors. Performance incentives for global health: Potential and pitfalls. Washington DC: Center for Global Development. 237-256.
24. Msellati P, Juillet-Amari A, Prudhomme J, Akribi H, Coulibaly-Traore D, et al. (2003) Socioeconomic and health characteristics of HIV-infected patients seeking care in relation to access to the Drug Access Initiative and to antiretroviral treatment in Cote d'Ivoire. AIDS 17: S63-68. (Pubitemid 36951671)
25. Louis C, Ivers L, Smith Fawzi M, Freedberg K, Castro A (2007) Late presentation for HIV care in central Haiti: Factors limiting access to care. AIDS Care 19: 487-491. (Pubitemid 46598753)
26. Mshana G, Wamoyi J, Busza J, Zaba B, Changalucha J, et al. (2006) Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: A qualitative study of early rural referrals to the national program. AIDS Patient Care St 20: 649-57.
27. Rosen S, Ketlhapile M, Sanne I, M DeSilva M (2007) Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med 97: 524-529. (Pubitemid 47091191)
28. Tuller D, Bangsberg D, Senkungu J, Ware N, Emenyonu N, et al. (2010) Transport costs impede sustained adherence and access to HAART in a clinic population in Southwest Uganda: A qualitative study. AIDS Beh 14: 778-784.
29. Bobrova N, Sarang A, Stuikyte R, Lezhentsev K (2007) Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: A regional overview. Int J Drug Pol 18: 313-318. (Pubitemid 47135598)
30. Zachariah R, Harries A, Manzi M, Gomani P, Teck R, et al. (2006). Acceptance of antiretroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. Plos One e121. doi:10.1371/journal.pone.0000121.
31. Brigido L, Rodrigues R, Casseb J, Oliviera D, Rossetti M, et al. (2001) Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Pat Care St 15: 587-593. (Pubitemid 33139486)
32. Muko K, Ngwa V, Chigang L, Meiburg A, Shu E (2004) Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: A rural case study in Cameroon. SAHARA J 1: 107-113.
33. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acq Immun Def Synd 34: 281-288. (Pubitemid 37377361)
34. Rosen S, Fox M, Gill C (2011) Patient retention in antiretroviral programs in Sub-Saharan Africa: A systematic review, PloS Medicine 4: e298.
35. Tassie J-M, Baijal P, Vitoria M, Alisalad A, Crowley S, et al. (2010) Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acq Immun Def Synd 54: 437-441.
36. Duff P, Kipp W, Wild T, Rubaale T, Okech-Ojony J (2010) Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda. J Int AIDS Soc 13: doi: 10.1186/1758-2652-13-37.
37. Moon S, Van Leemput L, Durier N, Jambert E, Dahmane A, et al. (2008) Out-of-pocket costs of AIDS care in China: Are free antiretroviral drugs enough? AIDS Care 20: 984-994.
38. Riyarto S, Hidayat B, Johns B, Probandari A, Mahendradhata Y, et al. (2010) The financial burden of HIV care, including antiretroviral therapy, on patients in three sites in Indonesia. Health Polic Plann 25: 272-282.
39. Russell S (2004) The economic burden of illness for households in developing countries: A review of studies focusing on malaria, tuberculosis and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg 71: 147-155.
40. Boccia D, Hargreaves J, Lönnroth K, Jaramillo E, Weiss J, et al. (2011) Cash transfer and microfinance interventions for tuberculosis control: review of the impact evidence and policy implications. Int J Tuberc Lung Dis 15: S37-49.
41. Kim M, Cox C, Anjalee D, Draper H, Kabue M, et al. (2012) Prompt initiation of ART with therapeutic food is associated with improved outcomes in HIV-infected Malawian children with malnutrition. J Acquir Immun Defic Syn 59: 173-176.
42. Lönnroth K, Jaramillo E, Williams B, Dye C, Raviglione M (2009) Drivers of tuberculosis epidemics: The role of risk factors and social determinants. Soc Sci Med 68: 2240-2246.
43. Moran-Mendoza O, Marion S, Elwood K, Patrick D, Fitrzgerald J (2010) Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 14: 1112-1119.
44. World Health Organization (2010) World Health Report. Health systems financing: The path to universal coverage. Geneva: World Health Organization.
45. UNAIDS (2010) UNAIDS Expanded Business Case: Enhancing Social Protection. Geneva: Joint United Nations Programme on HIV/AIDS.
46. International Labour Organization (ILO) (2011) Social protection floor for a fair and inclusive globalization. Geneva: International Labour Organization.
47. Buchanan R (1997) Compliance with tuberculosis drug regimes: Incentives and enablers offered by public health departments. Am J Pub Heal 87: 2014-2017.
48. Subbaro K, Bonnerjee A, Braithwaite J, Carvalho S, Ezemenan K, et al. (1997) Safety net programs and poverty reduction: Lessons from cross-country experience. Washington, DC: World Bank.
49. Kielmann K, Cataldo F (2010) Tracking the rise of the "expert patient" in evolving paradigms of HIV care. AIDS Care 22: 21-28.
50. Bridge J, Hunter B, Atun R, Lazarus J (2012) Global Fund investments in harm reduction from 2002 to 2009. Int J Drug Pol 23: 279-285.